🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the battle against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing globally, with data suggesting in excess of 82 million infections per year. Especially elevated rates are seen in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, the spread of superbugs and the highly restricted treatment choices presently on offer.”

Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The global health body has designated it as a "critical concern". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in December for use against gonorrhoea. This STI can lead to major issues, including infertility. Experts hope that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone represents a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Outcomes and Worldwide Availability

According to data released by a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This places it at an comparable level with the current standard treatment, which combines two antibiotics. The trial enrolled over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have expressed positive views. Having a single-dose, oral treatment of this kind is seen as a "critical tool" for gonorrhoea control. This is considered essential to reduce the burden of the illness for individuals and to halt the transmission of extremely resistant gonorrhoea globally.